SAN DIEGO, May 11, 2017 /PRNewswire/ -- Tocagen Inc.
(Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy
company, today announced it presented data at the American Society
of Gene and Cell Therapy 20th Annual Meeting
(ASGCT).
Details of the presentations are as follows. The presentation
slides and poster can be accessed by visiting the publications and
presentations section of the Company's website at
www.tocagen.com.
Title: Long-term follow-up data from 126 patients with
recurrent high grade glioma from three Phase 1 trials of Toca 511
and Toca FC: Update and justification for a Phase 2/3 trial
Presentation Type: Podium
Session: Immunotherapy Clinical Trials for Cancer
Presenter: Douglas Jolly,
Ph.D., executive vice president of research and pharmaceutical
development at Tocagen
Summary: As previously presented, data from three Phase 1
trials of Toca 511 and Toca FC in 126 patients with recurrent high
grade glioma demonstrate potential benefits, including durable
objective responses, extended overall survival and a favorable
safety profile.
Title: TOCA 511 & 5-FC: Anti-tumor activity, immune
memory and prolonged survival even at low infection levels
Presentation Type: Poster
Session: Cancer-Immunotherapy, Cancer Vaccines I
Presenter: Kader Yagiz,
Ph.D., research scientist at Tocagen
Summary: Data from preclinical models suggest that even a
small percentage of Toca 511 infection results in anti-tumor immune
activation and a significant increase in survival following 5-FC
treatment.
About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy
company developing first-in-class, broadly applicable product
candidates designed to activate a patient's immune system against
their own cancer. Tocagen is developing its lead investigational
product candidate, Toca 511 & Toca FC, initially for the
treatment of recurrent high grade glioma (HGG), a disease with
significant unmet medical need. Toca 511 & Toca FC was granted
Breakthrough Therapy Designation by the U.S. Food and Drug
Administration (FDA) for the treatment of recurrent HGG. Tocagen
has received grant support from leading brain cancer foundations,
including Accelerate Brain Cancer
Cure (ABC2), National Brain Tumor Society (NBTS),
American Brain Tumor Association (ABTA), Musella
Foundation and Voices Against Brain Cancer (VABC).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/tocagen-presents-data-at-the-american-society-of-gene-and-cell-therapy-20th-annual-meeting-300455756.html
SOURCE Tocagen Inc.